Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD74 | P04233 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KAT7 | O95251 | 4/20 | 0.46 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.46 |
| ▸ | KAT6B | Q8WYB5 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.43 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28853149 | 0.86 | ADRB2 (0.54) | KDM4ELMNAL3MBTL1KAT7KAT6A | |
| SCHEMBL20897187 | 0.75 | THRB (0.61) | KDM4ELMNAL3MBTL1KAT7KAT6A | |
| SCHEMBL29008820 | 0.75 | KDM4E (0.52) | KDM4ELMNAKAT7KAT6AKAT6B | |
| SCHEMBL10053919 | 0.75 | MEN1 (0.50) | LMNAL3MBTL1KAT7KAT6AKAT6B | |
| SCHEMBL11651609 | 0.74 | KDM4E (0.45) | CD74MIFKDM4ELMNAL3MBTL1 | |
| SCHEMBL10494079 | 0.74 | KDM4E (0.45) | CD74MIFKDM4ELMNAL3MBTL1 | |
| SCHEMBL10066968 | 0.74 | KMT2A (0.56) | LMNAL3MBTL1KAT7KAT6AKAT6B | |
| SCHEMBL4857301 | 0.74 | PDE4B (0.55) | LMNAKAT7KAT6AKAT6BMEN1 | |
| SCHEMBL31172495 | 0.73 | HTT (0.45) | KDM4ELMNAL3MBTL1KAT7KAT6A | |
| SCHEMBL464374 | 0.73 | CA12 (0.54) | KDM4ELMNAL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357603-B2 | Acyl sulfonamides for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2025-07-15 | — | — | US | disclosed |
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | CD74 4263/4885MIF 4807/4885KDM4E 461/4885 |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | KAT6A, KAT6B, KAT2A | CD74 4263/4885MIF 4807/4885KDM4E 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.